382 related articles for article (PubMed ID: 29477102)
61. Influence of Rituximab on Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma and Role of Prophylaxis--A Systematic Review of Prospective Studies.
Ghose A; Elias HK; Guha G; Yellu M; Kundu R; Latif T
Clin Lymphoma Myeloma Leuk; 2015 Aug; 15(8):451-7. PubMed ID: 25816933
[TBL] [Abstract][Full Text] [Related]
62. (R)-GEMOX chemotherapy for unfit patients with refractory or recurrent primary central nervous system lymphoma: a LOC study.
Collignon A; Houillier C; Ahle G; Chinot O; Choquet S; Schmitt A; Agape P; Soussain C; Hoang-Xuan K; Tabouret E
Ann Hematol; 2019 Apr; 98(4):915-922. PubMed ID: 30535802
[TBL] [Abstract][Full Text] [Related]
63. High Doses of Antimetabolites Followed by High-Dose Sequential Chemoimmunotherapy and Autologous Stem-Cell Transplantation in Patients With Systemic B-Cell Lymphoma and Secondary CNS Involvement: Final Results of a Multicenter Phase II Trial.
Ferreri AJ; Donadoni G; Cabras MG; Patti C; Mian M; Zambello R; Tarella C; Di Nicola M; D'Arco AM; Doa G; Bruno-Ventre M; Assanelli A; Foppoli M; Citterio G; Fanni A; Mulè A; Caligaris-Cappio F; Ciceri F
J Clin Oncol; 2015 Nov; 33(33):3903-10. PubMed ID: 26282634
[TBL] [Abstract][Full Text] [Related]
64. Performance status, comorbidities, and cycles of methotrexate exert the greatest influence on outcomes of primary and secondary CNS lymphomas: the Lexington experience.
Curry LD; Munker R; Li N; Yan D; Pryor P; Nozad S; Keller P; Monohan GP; Iragavarapu C; Krem MM
Ann Hematol; 2023 Jan; 102(1):141-154. PubMed ID: 36367559
[TBL] [Abstract][Full Text] [Related]
65. [CNS involvement and the feasibility of intratecal chemotherapy administration in patients with a nodal form of diffuse large B-cell lymphoma not otherwise specified. Data of prospective study].
Magomedova AU; Misyurina AE; Mangasarova JK; Gorenkova LG; Margolin OV; Fastova EA; Kravchenko SK
Ter Arkh; 2019 Jul; 91(7):35-40. PubMed ID: 32598734
[TBL] [Abstract][Full Text] [Related]
66. Central nervous system involvement in T-cell lymphoma: A single center experience.
Gurion R; Mehta N; Migliacci JC; Zelenetz A; Moskowitz A; Lunning M; Moskowitz C; Hamlin P; Horwitz S
Acta Oncol; 2016 May; 55(5):561-6. PubMed ID: 27046135
[TBL] [Abstract][Full Text] [Related]
67. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis.
Abrey LE; Moskowitz CH; Mason WP; Crump M; Stewart D; Forsyth P; Paleologos N; Correa DD; Anderson ND; Caron D; Zelenetz A; Nimer SD; DeAngelis LM
J Clin Oncol; 2003 Nov; 21(22):4151-6. PubMed ID: 14615443
[TBL] [Abstract][Full Text] [Related]
68. Clinicobiological features and prognostic impact of diffuse large B-cell lymphoma component in the outcome of patients with previously untreated follicular lymphoma.
Magnano L; Balagué O; Dlouhy I; Rovira J; Karube K; Pinyol M; Rivas-Delgado A; Costa D; Martínez-Trillos A; González-Farre B; Martínez-Pozo A; Giné E; Colomer D; Delgado J; Villamor N; Campo E; López-Guillermo A
Ann Oncol; 2017 Nov; 28(11):2799-2805. PubMed ID: 29045517
[TBL] [Abstract][Full Text] [Related]
69. Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients.
Caimi PF; William BM; Silva Rondon CH; Fu P; Cooper BW; Campagnaro EL; Gerson SL; Reese-Koc J; Fox R; Creger RJ; de Lima M; Lazarus HM
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1926-31. PubMed ID: 26087475
[TBL] [Abstract][Full Text] [Related]
70. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience.
Savage KJ; Al-Rajhi N; Voss N; Paltiel C; Klasa R; Gascoyne RD; Connors JM
Ann Oncol; 2006 Jan; 17(1):123-30. PubMed ID: 16236753
[TBL] [Abstract][Full Text] [Related]
71. Clinical presentation, treatment, and outcomes of patients with central nervous system involvement in extranodal natural killer/T-cell lymphoma.
Nevel KS; Pentsova E; Daras M
Leuk Lymphoma; 2019 Jul; 60(7):1677-1684. PubMed ID: 30648449
[TBL] [Abstract][Full Text] [Related]
72. Patterns of failure in advanced stage diffuse large B-cell lymphoma patients after complete response to R-CHOP immunochemotherapy and the emerging role of consolidative radiation therapy.
Shi Z; Das S; Okwan-Duodu D; Esiashvili N; Flowers C; Chen Z; Wang X; Jiang K; Nastoupil LJ; Khan MK
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):569-77. PubMed ID: 23540349
[TBL] [Abstract][Full Text] [Related]
73. Prevention and management of secondary central nervous system lymphoma.
Bobillo S; Khwaja J; Ferreri AJM; Cwynarski K
Haematologica; 2023 Mar; 108(3):673-689. PubMed ID: 36384246
[TBL] [Abstract][Full Text] [Related]
74. [Isolated central nervous system relapse of diffuse large B-cell lymphoma in the era of immunochemotherapy].
Krmek DZ; Ljubić N; Vrbanić L
Acta Med Croatica; 2012 Dec; 66(5):403-7. PubMed ID: 23814970
[TBL] [Abstract][Full Text] [Related]
75. Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials.
Maurer MJ; Habermann TM; Shi Q; Schmitz N; Cunningham D; Pfreundschuh M; Seymour JF; Jaeger U; Haioun C; Tilly H; Ghesquieres H; Merli F; Ziepert M; Herbrecht R; Flament J; Fu T; Flowers CR; Coiffier B
Ann Oncol; 2018 Aug; 29(8):1822-1827. PubMed ID: 29897404
[TBL] [Abstract][Full Text] [Related]
76. Analysis of clinical characteristics and outcome of patients with previously untreated diffuse large B-cell lymphoma and renal involvement in the rituximab era.
Lehners N; Krämer I; Schwarzbich MA; Ho AD; Witzens-Harig M
Leuk Lymphoma; 2016 Nov; 57(11):2619-25. PubMed ID: 26999040
[TBL] [Abstract][Full Text] [Related]
77. [Clinical pathologic characteristics and treatment outcomes of 19 relapsed pediatric B-cell lymphoma].
Huang S; Jin L; Yang J; Duan YL; Zhang M; Zhou CJ; Ma XL; Zhang YH
Zhonghua Er Ke Za Zhi; 2017 Oct; 55(10):748-753. PubMed ID: 29050112
[No Abstract] [Full Text] [Related]
78. The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma.
Arkenau HT; Chong G; Cunningham D; Watkins D; Agarwal R; Sirohi B; Trumper M; Norman A; Wotherspoon A; Horwich A
Ann Oncol; 2007 Mar; 18(3):541-5. PubMed ID: 17164228
[TBL] [Abstract][Full Text] [Related]
79. High-dose methotrexate is effective for prevention of isolated CNS relapse in diffuse large B cell lymphoma.
Ong SY; de Mel S; Grigoropoulos NF; Chen Y; Tan YC; Tan MSY; Ng LCK; Lee YS; Phipps C; Goh YT; Yong KY; Liu X; Chng WJ; Lim ST; Nagarajan C
Blood Cancer J; 2021 Aug; 11(8):143. PubMed ID: 34385415
[TBL] [Abstract][Full Text] [Related]
80. Impact of prior treatment on outcome of transformed follicular lymphoma and relapsed de novo diffuse large B cell lymphoma: a retrospective multicentre analysis.
Lerch K; Meyer AH; Stroux A; Hirt C; Keller U; Viardot A; Marks R; Schreiber S; Pezzutto A; Scholz CW
Ann Hematol; 2015 Jun; 94(6):981-8. PubMed ID: 25645656
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
